MCKESSON CORP (MCK): Results of Operations and Financial Condition
MCKESSON CORP (MCK) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 6 mck_exhibit991x6302026.htm EX-99.1 Document Exhibit 99.1 McKESSON REPORTS FISCAL 2027 FIRST QUARTER RESULTS AND RAISES FULL YEAR ADJUSTED EPS GUIDANCE IRVING, Texas, August 5, 2026 - McKesson Corporation (NYSE:MCK) today announced results for the first quarter ended Jun
How this was made
The 30-second read
Why it matters
The most tradable elements are the raised adjusted EPS guidance range, the 15% dividend increase, and the disclosed capital allocation (accelerated repurchase). Offsetting factors include GAAP EPS decline and negative free cash flow in the quarter, plus ongoing progress toward the planned separation of the Medical-Surgical Solutions segment (including the Wellverse naming).
Market read
Traders can update valuation and positioning based on the raised adjusted EPS outlook and shareholder return actions, while monitoring cash flow and GAAP earnings headwinds.
What to watch
The filing attributes GAAP EPS decline to a redemption value adjustment and bad-debt provision timing tied to Rite Aid bankruptcy, so traders should separate one-time items from underlying operating momentum.
Background
McKesson filed an SEC 8-K with Exhibit 99.1 reporting fiscal 2027 first-quarter results (ended June 30, 2026) and updating full-year adjusted EPS guidance.
Ticker impact
McKesson reported fiscal 2027 Q1 results and raised full-year adjusted EPS guidance to $44.20 to $45.00 from $43.80 to $44.60.
Likely positive reaction bias, with traders focusing on the adjusted EPS raise and dividend increase versus GAAP EPS decline and FCF weakness.
The filing discloses a specific guidance increase, a 20% YoY adjusted EPS per diluted share gain, and a 15% dividend hike, all of which are direct valuation catalysts; it also discloses negative free cash flow and GAAP EPS decline, which can cap upside.
Market effects
Reinforces demand momentum in North American Pharmaceutical distribution and growth in oncology and multispecialty, which can support sentiment for healthcare distribution peers.
Primarily US healthcare distribution read-through via prescription volume growth and specialty product distribution.
Limited direct global catalyst beyond multinational healthcare supply chain demand signals.
Counterpoint
The guidance is on non-GAAP adjusted EPS, while GAAP EPS fell and free cash flow was negative, suggesting quality of earnings and cash conversion may be weaker than the headline implies.
Key entities
- companyMcKesson Corporation
Reported fiscal 2027 Q1 results, raised full-year adjusted EPS guidance, increased quarterly dividend, and detailed progress on the Medical-Surgical Solutions separation.
- counterpartyApollo Funds
Purchased an approximately 13% minority interest in McKesson’s Medical-Surgical Solutions business for $1.25 billion.
- executiveThomas L. Rodgers
Retired as Executive Vice President, Chief Strategy and Business Development Officer effective Aug 1, 2026.
- executiveRamesh Srinivasan
Assumed role of Executive Vice President and Chief Strategy Officer effective Aug 1, 2026.
